


CLAIMS

1. Use of a compound of formula (II) or a pharmaceutically acceptable salt, solvate, or composition thereof, in the manufacture of a medicament for the treatment of metastatic brain cancer:




wherein:

Q is C-R¹⁰ or N


R⁹ is CH₃ or CH₂CH₂F; and

R¹⁰ is H or CH₃.

2. The use of claim 1, wherein Q is C-R¹⁰.
3. The use of claim 1 or 2, wherein R⁹ is CH₃.
4. The use of any one of claims 1 to 3, wherein Q is CH.
5. The use of claim 1, wherein the compound of formula (II) is further characterized by a structure of formula:




6. The use of claim 1, wherein the compound of formula (II) is further characterized by a structure of formula:



2


7. The use of claim 1 or 2, wherein R⁹ is CH₂CH₂F.

8. The use of claim 7, wherein the compound of formula (II) is further characterized by a structure of formula:



3

9. The use of claim 1, wherein the compound of formula (II) is selected from the group consisting of:



10. The use of any one of claims 1 to 9, the medicament is to be administered to the subject with a second therapeutic agent.


11. The use of claim 10, wherein said second therapeutic agent is a different EGFR modulator.

12. The use of claim 10, wherein said second therapeutic agent is a chemotherapeutic agent.

13. The use of any one of claims 1 to 12, wherein said metastatic brain cancer is developed from an EGFR-mediated non-small cell lung cancer.


14. The use of any one of claims 1 to 13, wherein the medicament includes a pharmaceutical composition comprising said compound of formula (II), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier that is to be administered to the subject.

15. The use of any one of claims 1 to 14, said compound of formula (II) is compound **1**.




1

16. The use of any one of claims 1 to 15, said compound of formula (II) is the methanesulfonic acid salt of compound **1** (**1·Ms**).



1·Ms

17. Use of a compound of formula **II** or a pharmaceutically acceptable salt, solvate, or composition thereof, in the manufacture of a medicament for the treatment of metastatic brain cancer:



II


wherein:

Q is C-R¹⁰

R⁹ is CH₃ or CH₂CH₂F; and

R¹⁰ is H or CH₃.

18. The use of claim 17, wherein the compound of formula (II) is selected from the group consisting of:



19. The use of any one of claims 17 to 18, wherein said metastatic brain cancer is developed from an EGFR-mediated non-small cell lung cancer.